We noticed you’re blocking ads

Thanks for visiting RetinaToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://supplements.retinatoday.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Summary and Closing Comments

Frank Holz

Novel, potent, and more durable therapies have the potential to address the remaining unmet need of treatment burden in nAMD. In the phase 3 studies HAWK and HARRIER, brolucizumab demonstrated noninferiority in BCVA and superior anatomical outcomes compared with aflibercept, with over half of patients maintained on a 12-week dosing interval up to 48 weeks. “Finally, looking forward, the phase 3b study TALON will provide us with evidence on the efficacy and safety of 6-mg brolucizumab compared to 2-mg aflibercept in a treat-to-control regimen,” said Prof. Holz.

© 2020 Novartis Pharma AG, CH-4002 Basel Switzerland February 2020 GLOPH/BRO/0235

author
Peter Kaiser
  • Financial disclosure: Consultant (Alcon, Allergan, Bayer, Chengdu Kanghong Pharmaceutical Group, Kodiak, Novartis, Regeneron)
author
Adrian Koh
  • Financial disclosure: Consultant (Alcon, Allergan, Bayer, Boeringher Mannheim, Carl Zeiss Meditec, Heidelberg Engineering, Novartis, Santen, Topcon)
author
Robin Hamilton
  • Financial disclosure: Consultant (Allergan, Bayer Healthcare, Novartis Pharmaceuticals, Roche), Grant support (Bayer Healthcare, Novartis Pharmaceuticals, Roche), Lecture fees (Allergan, Roche, Bayer Healthcare, Novartis)
author
Frank Holz
  • Financial disclosure: Consultant (Acucela, Alcon, Apellis, Avalanche, Bayer, Genentech, Grayburg, Heidelberg Engineering, Lin Bioscience, Novartis, Oxurion, Roche), Financial support (Acucela, Allergan, Bayer, Carl Zeiss Meditec, Centervue, Heidelberg Engineering, NightStarX, Novartis, Optos, Roche)

1. Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology. 2017;124:1753-1763.

2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106-116.

3. Barak Y, Heroman WJ, Tezel TH. The past, present, and future of exudative age-related macular degeneration treatment. Middle East Afr J Ophthalmol. 2012;19:43-51.

4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.

5. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209-213 e2.

6. Skaat A, Chetrit A, Belkin M, et al Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2012;153:214-221 e1.

7. Borooah S, Jeganathan VS, Ambrecht AM, et al. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye (Lond). 2015;29:1156-1161.

8. Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hiemic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011;129:709-717.

9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65 e5.

10. Holz FG. Data presented at EURETINA 2017.

11. American Society of Retina Specialists. Preferences and Trends (PAT) survey 2018.

12. Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration—a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16:31.

13. Rasmussen A, Brandi S, Fuchs J, et al. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration. Acta Ophthalmol. 2015;93:616-620.

14. Real JP, Granero GE, De Santis MO, et al. Rate of vision loss in neovascular age-related macular degeneration explored. Graefes Arch Clin Exp Ophthalmol. 2015;253:1859-1865.

15. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1-24.

16. Waldstein SM, Simader C, Staurenghi G, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123:1521-1529.

17. Schmidt-Erfurth U, Waldstein SM, Deak GG, et al. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822-832.

18. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144-1167.

19. Royal College of Ophthalmologists. Age-related macular degeneration: guidelines for management. 2013. Available at: http://www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-318-RCOphth-AMD-Guidelines-Sept-2013-FINAL-2.pdf. Accessed November 2019.

20. American Academy of Ophthalmologists. Age-related macular degeneration preferred practice pattern. 2015. Available at: https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015. Accessed November 2019.

21. Lanzetta P, Loewenstein A, Vision Academy Steering C. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259-1273.

22. Wykoff CC, Clark WL, Nielsen JS, et al. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018;24:S3-S15.

23. Khurana R. Safety and efficacy of abicipar in patients with neovascular age‐related macular degeneration. AAO 2018. [Oral presentation].

24. Allergan and molecular partners announce topline safety results from MAPLE study of abicipar pegol [news release]. Molecular Partners. https://www.molecularpartners.com/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol/. Accessed September 2019.

25. Khanani A. Simultaneous inhibition of VEGF and Ang-2 with faricimab in neovascular AMD: STAIRWAY phase II results. AAO. 2018. [Oral presentation].

26. Clinicaltrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (TENAYA). Available at: https://clinicaltrials.gov/ct2/show/NCT03823287. Accessed November 2019.

27. Clinicaltrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (LUCERNE). Available at: https://clinicaltrials.gov/ct2/show/NCT03823300. Accessed November 2019.

28. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72-84.

29. Novartis receives FDA approval for Beovu, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept [news release]. Novartis. October 8, 2019. https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept. Accessed November 2019.

30. Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology. 2016;123:1080-1089.

31. Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296-1304.

32. Bayer Pharma AG. Eylea summary of product characteristics. Available at: www.ema.europa.eu. 2017. Accessed November 2019.

33. Novartis Pharma AG. Lucentis summary of product characteristics. August 2018. Available at: https://www.ema.europa.eu/documents/product-information/lucentis-epar-product-information_en.pdf. Accessed October 31, 2018.

34. Tietz J, Spohn G, Schmid G, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor A for the treatment of retinal disorders. Invest Ophthalmol Vis Sci. 2015;56:1501.

35. Dugel P. Phase 3, randomized, double-masked, multicenter trials of brolucizumab vs. aflibercept for neovascular AMD: ninety-six-week results from the HAWK and HARRIER studies. AAO 2018. [Oral presentation].

36. Clinicaltrials.gov. Study to assess the efficacy and safety of brolucizumab 6mg compared to aflibercept 2 mg in a treat-to-control regimen (TALON). Available at: https://clinicaltrials.gov/ct2/show/NCT04005352. Accessed November 2019.

37. Gillies MC, Hunyor AP, Arnold JJ, et al. Macular atrophy in neovascular age-related macular degeneration: A randomized clinical trial comparing ranibizumab and aflibercept (the RIVAL study). Ophthalmology. 2019.

You've reached the end of this month's issue, thanks for reading!

Read our latest issues:
Improved Technology, Speedier Clinics, and Tailored Treatments
Read Issue

Improved Technology, Speedier Clinics, and Tailored Treatments

Treatment Adherence in Neovascular AMD 2
Read Issue

Treatment Adherence in Neovascular AMD 2

Treatment Adherence in Neovascular AMD
Read Issue

Treatment Adherence in Neovascular AMD

Next Article